Key facts
| Recalling firm | Fresenius Kabi USA, LLC |
|---|---|
| Manufacturer | Fresenius Kabi USA, LLC |
| Brand name | TYENNE |
| Product description | Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, Rx Only, Manufactured by Fresenius Kabi USA, LLC, Lake Zurich, Illinois, 60047, NDC 65219-594-20. |
| Classification | Class I |
| Recall number | D-0827-2026 |
| Report date | Not disclosed in the FDA record. |
| Status | Ongoing |
| Reason for recall | Presence of particulate matter:An internal investigation at the firm found the product to contain glass particles. |
What consumers should do
Facilities, clinicians, and consumers holding an affected unit or lot of Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, Rx Only, Manufactured by Fresenius Kabi USA, LLC, Lake Zurich, Illinois, 60047, NDC 65219-594-20. should stop using it for the purpose described in the recall notice and hold remaining stock pending instructions from Fresenius Kabi USA, LLC. FDA recall records typically direct the recalling firm to notify known accounts directly with a recall letter describing the specific corrective action -- replacement, field correction, refund, or return. Anyone who received the product through a distributor rather than directly from Fresenius Kabi USA, LLC should confirm with their supplier whether their specific lot or unit is on the affected list, since recall notices are lot- or unit-specific and not every unit of a product line is necessarily included. Questions about a specific unit's status should go to Fresenius Kabi USA, LLC directly or to the distributor that supplied it; Argus HQ is a public-record aggregator, not the recalling firm, and cannot confirm individual unit status.
What this classification means
A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death. This classification does not mean harm has already occurred in every case -- it reflects FDA’s assessment of the realistic worst-case risk profile of the defect described in the recall, based on the reason for recall reported by the firm. Class I recalls receive the closest FDA monitoring of the three classes: the recalling firm typically must submit a recall strategy, periodic status reports, and effectiveness checks confirming that the affected lots have actually been removed from distribution or corrected in the field. FDA's Center for Devices and Radiological Health (for devices) or Center for Drug Evaluation and Research (for drugs) reviews the classification and can require additional corrective action if the initial response is judged insufficient. Because this record is filed as Class I, professionals and consumers handling an affected lot should treat FDA's own classification -- not this page's summary of it -- as the authoritative risk signal. A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death. This classification does not mean harm has already occurred in every case -- it reflects FDA’s assessment of the realistic worst-case risk profile of the defect described in the recall, based on the reason for recall reported by the firm. Class I recalls receive the closest FDA monitoring of the three classes: the recalling firm typically must submit a recall strategy, periodic status reports, and effectiveness checks confirming that the affected lots have actually been removed from distribution or corrected in the field.
Frequently asked questions
- What is the FDA recall number for this event?
- FDA recall number D-0827-2026.
- What is the current status of this recall?
- Status as recorded by FDA: Ongoing.
- Where can I verify this recall directly with FDA?
- The verbatim FDA record is the source of truth for every recall Argus HQ tracks — always confirm against fda.gov before acting.
- Is Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL) recalled?
- Yes. FDA lists a Class I recall by Fresenius Kabi USA, LLC for Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, Rx Only, Manufactured by Fresenius Kabi USA, LLC, Lake Zurich, Illinois, 60047, NDC 65219-594-20., reported 20260902, with status "Ongoing." FDA recall number: D-0827-2026.
Know if this happens again — we'll email you.
Free. No spam, just recall alerts for what you tell us to watch.
Related enforcement actions
Full FDA history for Fresenius Kabi USA, LLCCompiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Class I Recall: TYENNE by Fresenius Kabi USA, LLC — Recall Details. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/recall/fresenius-kabi-usa-d-0827-2026-2026-09-02
"FDA Class I Recall: TYENNE by Fresenius Kabi USA, LLC — Recall Details." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/recall/fresenius-kabi-usa-d-0827-2026-2026-09-02.
Argus HQ Research. "FDA Class I Recall: TYENNE by Fresenius Kabi USA, LLC — Recall Details." Digital Empire Holdings LLC. Accessed September 8, 2026. https://argushq.ai/recall/fresenius-kabi-usa-d-0827-2026-2026-09-02.
@misc{argushq_argushq_ai_recall_fresenius_kabi_usa_d_0827_2026_2026_09_02_2026,
title = {FDA Class I Recall: TYENNE by Fresenius Kabi USA, LLC — Recall Details},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/recall/fresenius-kabi-usa-d-0827-2026-2026-09-02},
note = {Accessed: September 8, 2026}
}Source: FDA.gov — Recalls ↗

